Concepedia

Richard Heng

RH

Statistics

Publications

13

Citations

471

H-Index

13

Active since

1985

Affiliations

Novartis Institutes for BioMedical Research(Current)

Novartis (Switzerland)

Sanden (Japan)

Richard Heng is an author at Novartis Institutes for BioMedical Research specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

1985–2021

13

Publications

13

Expression, Refolding, and Autocatalytic Proteolytic Processing of the Interleukin-1β-converting Enzyme Precursor

Paul Ramage, Dominique Cheneval, Maria Chvei et al. · Journal of Biological Chemistry · 1995 · 107 citations · Full text

, , +17

Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity

Achim Schlapbach, Roland Feifel, Stuart Hawtin et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 48 citations · Full text

, , +10

Synthesis of P1 aspartate-based peptide acyloxymethyl and fluoromethyl ketones as inhibitors of interleukin-1β-converting enzyme

Láśzló Révész, Chantal Briswalter, Richard Heng et al. · Tetrahedron Letters · 1994 · 42 citations

, , +15

Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy

Juraj Velcicky, Roland Feifel, Stuart Hawtin et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 42 citations · Full text

, , +14

A disorder-related variant (E420K) of a PP2A-regulatory subunit (PPP2R5D) causes constitutively active AKT-mTOR signaling and uncoordinated cell growth

Cinta M. Papke, Kali A. Smolen, Mark R. Swingle et al. · Journal of Biological Chemistry · 2021 · 42 citations · Full text

, , +17

1–5 of 13